Navigation Links
Promising strategy for treatment of lung cancer
Date:3/29/2010

A research team at the Sahlgrenska Academy at the University of Gothenburg, Sweden, has shown in a study that two closely related enzymes could be targets for the treatment of lung cancer. The discovery was made when the researchers blocked the production of the two enzymes in transgenic mice. This resulted in inhibition of cell growth, fewer tumours and greater survival among the mice.

The article is being published in the journal Proceedings of the National Academy of Sciences (PNAS). With many types of cancer, the growth and spread of tumours is stimulated by Ras and Rho proteins. For these proteins to function, they need to be modified by the closely related enzymes FT and GGT. A number of pharmaceutical companies have therefore developed substances that reduce the activity of these two enzymes with the aim of inhibiting the function of Ras and Rho proteins and so slowing the development of the disease.

However, treatment with various substances to block these two enzymes has often been non-specific, and their efficacy has varied widely. This has made it difficult for researchers to assess the true potential of these enzymes as targets for medicines.

"We therefore developed genetic strategies in mice, known as transgenic mice, to switch off the genes coding for FT and GGT, enabling us to investigate whether a complete blockade of FT or GGT can inhibit the development of lung cancer, and whether this has side-effects in the lungs," explains researcher Anna-Karin Sjgren, who led the study together with Meng Liu, both from the Department of Clinical and Molecular Medicine.

In their study, the researchers used transgenic mice which produce a mutated Ras protein that causes lung cancer. First, production of FT or GGT in these mice's lungs was stopped by switching off the relevant genes.

"When we turned off the FT gene, the mice developed fewer lung tumours and lived longer," says Meng Liu. "At cellular level, the blockade of FT meant that the tumour cells were no longer able to divide. When we blocked the production of GGT, we saw the same effects: inhibition of cell growth, fewer lung tumours and improved survival."

In experiments where both genes were switched off at the same time, the number of lung tumours dropped sharply and the mice lived much longer. This means that the absence of these two enzymes does not have any obvious side-effects in the lungs, and that lung tumour cells seem to be more sensitive to the treatment than normal lung cells.

"Our findings show that FT and GGT are promising targets for the treatment of lung cancer," the researchers explain. "The next step in our research is to find out whether blocking these enzymes can have side-effects in other tissues."


'/>"/>

Contact: Anna-Karin Sjgren
anna-karin.sjogren@wlab.gu.se
46-031-342-4723
University of Gothenburg
Source:Eurekalert

Related medicine news :

1. SBRT eliminates tumors with promising survival for early-stage inoperable lung cancer patients
2. New smoking cessation therapy proves promising
3. Lacosamide validated as promising therapy for uncontrolled partial-onset seizures
4. Sytropin HGH Shows Promising Anti-Aging Results
5. New strategy produces promising advance in cancer vaccines
6. Promising therapy for relapsing multibple sclerosis
7. First blinded study of venous insufficiency prevalence in MS shows promising results
8. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
9. Promising new neuroimaging techniques for early detection of Alzheimers disease
10. LSUHSC research yields promising stroke treatment
11. Promising New Results On The Added Safety Of Using SmokeStik Electronic Cigarettes In The Bid To Quit Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... to its innovative Unified Instance Manager architecture, meeting the needs of multichannel ... version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides greater ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, ... organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among the ...
(Date:12/8/2016)... , ... December 08, 2016 , ... California Senate Bill ... payments per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical ... Institute (WCRI) . , According to the study, medical payments per claim in California ...
(Date:12/8/2016)... NC (PRWEB) , ... December 08, 2016 , ... ... Medicare and the Affordable Care Act. Dr. Botelho advocates for the mass media ... story movement gives people ongoing opportunities to share their unfortunate experiences; such a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Dickinson Insurance and Financial Services, ... Little Rock, has initiated a charity drive to provide support and funding to ... Senior Hunger, Arkansas ranks first in senior hunger statewide, third in child hunger, ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has been recognized ... Top Workplaces National Standard. To learn more about ... ... Inc.) ... survey administered by WorkplaceDynamics, LLC, a research firm specializing in organizational ...
(Date:12/8/2016)... -- Research and Markets has announced the addition of ... Type, Application, Usability - Forecast to 2025" report to their ... , , ... to grow at a CAGR of around 3.2% from 2015 to ... include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in ...
(Date:12/8/2016)... HARRISBURG, Pa. , Dec. 8, 2016 /PRNewswire-USNewswire/ ... and Secretary of Drug and Alcohol Programs ... anxiety and insomnia medications, known as benzodiazepines, developed ... "Benzodiazepines are medications that are frequently ... "However, when they are used with opioid pain ...
Breaking Medicine Technology: